Can machine learning help with the treatment of heterogeneity?

Scientists are using machine learning to help identify favorable treatment responses.

Randomized Control Trials (RTC) are a critical method used to identify the treatment effect of heterogeneity.

This process is becoming easier and more effective by utilizing machine learning to isolate subjects who warrant additional study.

In addition, machine learning has become state of the art. It has predictive abilities, thanks to its in-depth data analysis.

Furthermore, RTC can produce false positives. These can make sorting through the data tedious and time-consuming.

Machine learning can be applied to data analysis. This is occurring using a highly advanced algorithm. Machines incorporate helpful data to become more identifiable.

Moreover, this gives researchers a new level of control and customization. These new levels could potentially lead to more robust and transparent research results.

3 Key Points:

  1. RTCs produce false positives making deciphering the data difficult.
  2. Machine learning can help sort, filter, exclude, and highlight data the researcher defines, making it easier to analyze that data.
  3. Machine learning is advancing and beneficial, due in part to its ability to control false positives, create subgroups, and its predictive capabilities.

Source: https://bit.ly/2y5OM7Z

“The growing accessibility and recording of data modalities, arising from genetics, medical imaging, mobile devices, genomics, and electronic health records captured on trial participants, alongside breakthroughs in machine learning (ML) provide new opportunities for scientific discovery of patient strata exhibiting systematic variation in treatment effect.Watson, J.A., Holmes, C.C stated via the trialsjounral.biomedcentral.com

#ClinicalTrials, #DigitalHealth, #ClinicalData

P.S. Get new Digital Healthcare Article Summaries in your inbox, free. Click here to learn more.

Latest news

ACTide by Nubilaria against COVID-19

DECEIVER trial for COVID-19 related ARDS intensive care

Read more
Nubilaria ACTide @ Direct to Patient digital experience

Direct-to-Patient and Virtual Clinical Trials – Digital Experience

Read more
Nubilaria ACTide @ BIO Digital

BIO Digital

Read more

Want more information about our solutions?
Contact us today.

I've read and accept theTerms and Conditions and the Privacy Policy
   I would like to receive information about products and services via traditional mail, telephone, email and automated communication systems